# Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir

> **NCT00708162** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 724 (actual)

## Conditions studied

- HIV Infection

## Interventions

- **DRUG:** Elvitegravir
- **DRUG:** Raltegravir
- **DRUG:** EVG placebo
- **DRUG:** RAL placebo
- **DRUG:** Background regimen

## Key facts

- **NCT ID:** NCT00708162
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2010-12
- **Final completion:** 2015-04
- **Target enrollment:** 724 (ACTUAL)
- **Last updated:** 2016-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00708162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00708162, "Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00708162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*